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Abstract 
New blood formation or angiogenesis has become a key target in therapeutic strategies aimed at inhibiting tumor 
growth and other diseases associated with neovascularization. Angiogenesis is associated with important 
extracellular remodeling involving different proteolytic systems among which the plasminogen system plays an 
essential role. It belongs to the large serine proteinase family and can act directly or indirectly by activating 
matrix metalloproteinases or by liberating growth factors and cytokines sequestered within the extracellular 
matrix. Migration of endothelial cells is associated with significant upregulation of proteolysis and conversely, 
immunoneutralization or chemical inhibition of the system reduces angiogenesis in vitro. On the other hand 
genetically altered mice developed normally without overt vascular anomalies indicating the possibility of 
compensation by other proteases in vivo. Nevertheless, they have in some experimental settings revealed 
unanticipated roles for previously characterized proteinases or their inhibitors. In this review, the complex 
mechanisms of action of the serine proteases in pathological angiogenesis are summarized alongside possible 
therapeutic applications. 
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Introduction 
Angiogenesis, the formation of new blood vessels from pre-existing ones is essential for sustained tumor growth 
because it allows oxygenation and nutrient perfusion of the tumor as well as removal of waste products. 
Moreover, increased angiogenesis coincides with increased tumor cell penetration into the circulation and thus 
promotes metastasis. Tumor vessels develop by sprouting or intussusception from pre-existing vessels [1].         
In addition, circulating endothelial precursors mobilized from the bone marrow can also contribute to tumor 
angiogenesis [2]. Angiogenesis is controlled by the net balance between molecules that have positive and 
negative regulatory activity [1, 3, 4]. This observation has led to the concept of the 'angiogenic switch' in which 
the endothelial activation status is determined by the induction of positive regulators and/or the loss of negative 
regulators [5]. Positive regulators include at least the vascular endothelial growth factor (VEGF) family, 
fibroblast growth factors (FGFs), an-giopoietins, cytokines, chemokines, and their tyrosine kinase receptors.          
An increasing number of negative regulators have been identified such as inhibitors of proteinases, 
thrombospondins, interferons, chemokines (IP-10 and PF-4), bioactive fragments of the extracellular matrix 
(ECM) and other molecules [3, 4]. While not the subject of this review, in addition to induction of vascular 
permeability, proliferation and chemotaxis, VEGFs control endothelial cell survival, an activity necessary to 
maintain immature vessel integrity during neovascularization [6]. 
VEGF also increases the expression of matrix metallo-proteinases (MMPs) and protease inhibitors [1]. VEGF 
expression is upregulated in hypoxia by binding of the hypoxia-inducible factor 1 (HIF-1) to its promoter. HIF-1 
itself is regulated via its HIF-1 alpha subunit. Cells lacking a normal von Hippel-Lindau (VHL) tumor 
suppressor gene show high expression of VEGF due to constitutive stabilization of HIF-1 alpha [7]. At a later 
stage, angiopoietin 1 stabilizes the endothelial network by stimulating the interactions between endothelial and 
perien-dothelial cells, and reducing vascular permeability [1]. The formation of a provisional ECM is a hallmark 
of an-giogenesis. Angiogenic factors, most notably VEGF produced by tumor cells, induce hyperpermeability 
resulting in the extravasation of plasma proteins including at least fibrinogen, prothrombin, and vitronectin. 
Tissue factor through the activation of thrombin triggers the formation of fibrin [8]. Together with other adhesive 
proteins such as vitronectin, laminin, and fibronectin, fibrin forms a provisional matrix which supports 
angiogenesis and tumor growth [9]. These matrix components control cell proliferation, migration, survival, and 
apoptosis through interactions with adhesion molecules expressed at the cell surface. Important adhesion 
molecules include the integrins αvβ3 and αvβ5, receptors for fibrin and vitronectin [10-12]. Blockage of αvβ3 and 
αvβ5 integrins withmon-oclonal antibodies or small-molecule inhibitors prevents tumor growth and angiogenesis 
in animal models [13]. However, tumor-induced angiogenesis occurs and is actually enhanced in β3 -deficient 
mice and β3/β5 double-knockout mice [14]. These apparently paradoxical data may suggest that rather than being 
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required for angiogenesis, avβ3 and avβ5 integrins might normally function to limit it, and that the real effect of 
integrin-blocking agents was actually the activation of integrins, a process referred to as the 'integrin-mediated 
death pathway', leading to inhibition of neovascularization [15]. In an ocular model of hypoxia-induced retinal 
neovascularization, blockage of integrins in p53 null mice was ineffective in preventing pathological retinal 
angiogenesis suggesting that αv integrins and p53 act in concert [16]. During angiogenesis, extracellular 
proteolysis has been implicated in different steps such as provisional matrix remodeling, basement membrane 
degradation, and cell migration and invasion. Besides degrading ECM components, proteinases have also been 
implicated in the activation of cytokines, as well as in the release of growth factors sequestered within the ECM 
[17-19]. The group of proteinases involved in ECM remodeling comprises four different families based on the 
nature of the chemical group responsible for catalytic activity: the serine, cysteine, aspartic and 
metalloproteinases [20]. The present review will focus on a serine proteinase family, the plasminogen system 
which is involved in fibrinolysis, and in the degradation of ECM either directly or indirectly by activating 
MMPs. Over the last decade, mice deficient in one of the plasminogen system components have been generated 
allowing to study directly their role in disease [21-27]. 
The plasminogen system 
The plasminogen system is composed of several protein members: (i) plasminogen, an inactive proenzyme; (ii) 
urokinase (uPA) and tissue-type (tPA) plasminogen activators, two serine proteinases which convert 
plasminogen into plasmin; (iii) uPAR, a glycosylphosphatidylinositol (GPI)-linked surface receptor for uPA, and 
(iv) plasminogen activator inhibitors type 1 and type 2 (PAI-1 and PAI-2) belonging to the serine proteinase 
inhibitor (ser-pin) family (fig. 1). While sharing in common a plasminogen-converting function, the two types of 
plasminogen activator (uPA and tPA) have distinct structural and functional features. Briefly, tPA acts mainly as 
a fibrin-dependent and intravascular activation enzyme which is primarily involved in clot dissolution [28]. In 
contrast, uPA operates as a fibrin-independent, largely cell surface receptor-bound plasminogen activator and 
controls pericellular proteolysis [29-31]. 
The uPA molecule is composed of two major functional domains: the growth factor domain at the N terminus 
which binds uPAR and the catalytic domain at the C terminus. The activities of the uPA system are initiated 
through a cascade of events originating with uPAR. uPA is secreted as an inactive single-chain proenzyme 
(scuPA) which binds to uPAR present on many cell types. Cleavage of pro-uPA yields the active enzyme 
consisting of two disulfide-linked chains. In addition to plasmin, several proteinases including factor XIIa, 
cathepsin B, and kalikrein have been shown to activate scuPA as well. However, the physiological relevance of 
some of these proteinases is still questionable [32, 33]. Plasmin remains as the most likely physiological 
activator of scuPA [34]. Each molecule of plasmin can amplify this cascade by activating many more molecules 
of scuPA, a process which is made very efficient by the localization of both plasminogen and scuPA (by binding 
to uPAR) to the cell surface. Plasmin binding on its receptors is mediated by the lysine-binding site (LBS) 
associated with the kringle domain of plasmin(ogen). As a consequence of binding, plasminogen activation is 
enhanced while at the same time being partially protected from inactivation by circulating alpha2-an-tiplasmin 
[35]. However, ligated plasmin can still be inactivated by aprotinin, which competes with fibrin for the plasmin 
active site. There is a growing list of ubiquitous plasminogen receptors, including alpha-enolase, cytokeratin 8, 
and annexin 11 [36]. Plasmin displays a broad spectrum activity, and is able to degrade many glycoproteins 
(laminin, fibronectin) and proteoglycans of the ECM, as well as fibrin, and to activate other proteinases such as 
pro-metalloproteinases (MMP-1, MMP-3 and MMP-9). Plasmin can also activate or release growth factors from 
the ECM including latent transforming growth factor (TGF-β), basic fibroblast growth factor (bFGF), and VEGF 
[18]. 
Thus, uPA present at the cell surface is generally believed to initiate a proteinase cascade which in turn leads to 
the activation of plasmin, the breakdown of the ECM, and the activation and/or release of cytokines/chemokines 
or growth factors, thereby promoting cellular migration. However, various observations indicate that the role of 
the PA system in cell migration is not limited to the induction of matrix destruction. In concert with uPAR and 
PAI-1, uPA is involved in mitogenic, chemotactic, adhesive, and migratory cellular activities [37-39]. In 
addition, uPAR is involved in intracellular signaling, and cannot be considered as a simple molecule that 
localizes uPA at the cell surface [31,40]. The binding of uPA to its cell surface receptor concentrates uPA 
activity to the so-called 'focal adhesion sites' on the cell surface. The uPA/uPAR complex interacts with 
vitronectin, a multifunctional ECM glycoprotein and with β1 and β3 integrins, thereby participating in cell 
anchoring and migration [41]. In addition, despite the lack of a transmembrane domain, uPAR colocalizes with 
caveolin which can bind signaling molecules and stimulate signal transduction through uPAR [42-44]. However, 
the role of uPAR in intracellular signaling will not be discussed in detail in this review. 
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Figure 1. The plasminogen/plasmin system in pericellular proteolysis. Plasmin plays a central role by activating 
matrix metalloproteinases (MMPs) or by degrading extracellular matrix components. uPAR participates both in 
uPA activation, cell adhesion, and migration, as well as in signal transduction. The inhibitor PAI-1 exerts 
different effects by controlling the activity of plasminogen activators (tPA and uPA) and by regulating cell 
adhesion and migration through its interaction with vitronectin (see also fig. 2). 
 
 
Physiological inhibitors of the plasminogen system 
Different specific, physiological inhibitors of both plasmin (alpha2-antiplasmin) and plasminogen activators 
(PAI-1 and PAI-2) control the proteolytic activity along the serine proteinase cascade. PAI-1 is believed to be the 
most abundant fast-acting inhibitor of uPA in vivo. It is secreted in an active, but conformationally unstable 
form. The lack of disulfide bond to stabilize its ternary structure is likely to confer on the PAI-1 molecule a high 
degree of conformational plasticity. Free active PAI-1 spontaneously decays into an inactive 'latent' form when 
in solution in the test tube, or following its secretion in cell culture medium [45]. However, its inhibitory activity 
is stabilized and prolonged by binding to vitronectin present in plasma, platelets, and ECM [46-48]. The high 
affinity between vitronectin and PAI-1 raises the possibility that vitronectin may concentrate and localize PAI-1 
inhibitory activity to specific tissue areas. Vitronectin is thus considered as a cofactor for PAI-1, regulating both 
its activity and localization (fig. 2). 
PAI-1 binds not only to free uPA, but also to uPAR-bound uPA. The uPA/PAI-1 complex also interacts with the 
transmembrane α2-macroglobulin receptor low-density lipoprotein (LDL) receptor-related protein (LRP), an 
endocytic receptor. Through the combined action of uPAR and LRP, the uPA/PAI-1 complex is internalized and 
degraded in lysosomes, whereas the uPAR is recycled back to the cell surface [29, 38]. PAI-1 is believed to play 
a central role in cell adhesion mediated through integrins or the uPAR/uPA complex ([40, 46]. PAI-1 competes 
with the binding of vitronectin to different integrins such as αvβ1, αvβ3, αvβ5, α11bβ3, and α8β1 [49]. Accordingly, 
PAI-1 inhibits integrin-dependent migration of human amnion WISH cells, human carcinoma Hep-2 cells, and 
smooth muscle cells on vitronectin [50, 51]. It also promotes cellular migration by decreasing cell adhesion to 
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vitronectin [52]. This could explain the release of cells from this matrix protein by an excess of PAI-1. 
Therefore, the delicate balance between cell adhesion and cell detachment has been proposed to be governed by 
PAI-1 [53]. 
 
Figure 2. PAI-1 and uPAR are multifunctional molecules. uPAR interacts with different cell surface-associated 
molecules (integrins) and with the extracellular matrix glycoprotein, vitronectin. When PAI-1 is bound to 
vitronectin, integrin or uPAR-mediated adhesion is inhibited leading to cell detachment. 
 
 
The plasminogen system and angiogenesis 
Quiescent endothelial cells constitutively express t-PA, but net proteolysis is prevented by concomitant 
expression of PAI-1 [30, 54]. In contrast, when endothelial cells migrate, they upregulate uPA, uPAR and PAI-1 
[55-58]. Hypoxia, a major stimulus for angiogenesis has been reported to increase uPAR and PAI-1 expression 
in endothelial cells [59]. A variety of angiogenic factors (cytokines and growth factors) control the expression of 
the plasminogen system. VEGF and bFGF synergically induce the expression of uPA, tPA, uPAR, and PAI-1, 
whereas TGF-β downregulates uPA and enhances PAI-1 production [30]. Depending on the situation, PAI-1 is 
expressed either by endothelial cells themselves or by nonendothelial (stromal and epithelial) cells where it is 
thought to play a role in the preservation of matrix integrity [30]. In a coculture system of endothelial cells and 
fibroblasts, PAI-1 mRNA and promoter activity are induced only in a single row of fibroblasts apposed to 
sprouting but not resting endothelium [60]. Such a paracrine induction may be of importance during sprouting, 
which constitutes the only period during which endothelial cells establish direct contact with fibroblasts, and 
may provide a mechanism to counterbalance excessive pericellular proteolysis. 
Although inhibition of plasminogen activators reduces endothelial cell migration in vitro, surprisingly, 
embryonic and postnatal development was unperturbed in mice deficient in uPA and/or tPA, PAI-1, uPAR, 
plasminogen, or alpha2-antiplasmin [21-27, 30]. Whether this relates to the uselessness of these proteinases in 
embryonic vessel development or to redundancy or compensation remains to be established. A study on wound 
healing in plasmino-gen-deficient mice reported that although keratinocyte migration is severely impaired, 
angiogenesis is not affected in these mice [61]. Although developmental and wound healing-associated 
angiogenesis appears unaffected in uPA-, uPAR-, tPA-deficient mice, several in vivo studies provide evidence 
that this proteolytic system is implicated during various pathological angiogenic processes [30]. In the eye, uPA 
and uPAR are upregulated during development of retinal neovascuarization, which is significantly reduced in 
uPAR-deficient animals. Regarding tumoral angiogenesis, an increasing number of clinical studies have 
demonstrated that high uPA, uPAR, and PAI-1 levels indicate a poor prognosis for the survival of patients 
suffering from a variety of cancers [29, 49, 62, 63]. However, if these high levels are due to tumoral expression, 
to increased expression by reactive stromal cells recruited to the neoplastic environment, or to both mechanisms 
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is unclear. In fact, localization of the protein and mRNA of uPA, uPAR and PAI-1 varies among tumor types. In 
colon carcinoma, uPA is expressed in cancer cells and PAI-1 is found in endothelial cells [64, 65]. In breast 
cancer, uPA, uPAR and PAI-1 are expressed in cancer cells and the surrounding stromal cells [66-68]. However, 
in breast cancer, the expression in fibroblasts rather than in tumor cells seems to have the most impact on the 
clinical behavior of the disease [69]. The importance of uPA-uPAR interactions during angiogenesis has been 
documented in a number of in vivo systems [42]. Thus, uPAR antagonists have been developed and tested in 
various in vivo models (see below). For example, a fusion protein consisting of the receptor-binding amino-
terminal fragment of uPA (ATF) and the Fc portion of human IgG inhibit bFGF-induced angiogenesis in 
subcutaneously injected Matrigel [70]. Similarly, adenovirally delivered ATF specifically inhibits tumor 
angiogenesis in syngeneic and xenograft murine tumor models [71]. Microvessel density is markedly reduced in 
tumors developed upon injection of tumor cells transfected with a mutant murine uPA that retains receptor 
binding but not proteolytic activity [72]. 
Tumor induced by polyomavirus middle T (PymT) is regarded as a model of endothelial cell tumors and the 
derived PymT-transformed endothelial cells (End.cells) are suitable to study in vitro the morphogenic behavior 
of endothelial cells in three-dimensional fibrin gels [73]. The End. cells with increased plasminogen activator 
activity when compared to nontransformed endothelial cells form cystlike structures when embedded into a 
fibrin gel. Inhibition of plasmin restores normal morphogenic properties. These findings clearly implicate 
increased plasminogen activator-plasmin-mediated proteolysis in aberrant vascular morphogenesis [74]. 
Injection of End. cells into uPA-, tPA-, PAI-1-, or plasminogen-deficient mice demonstrates that tumor growth 
in vivo is dependent on the generation of uPA-mediated plasmin [75, 76]. Together, these studies emphasize the 
importance of balanced proteolysis for angiogenesis and give rise to a model explaining the dual role of 
proteinases and inhibitors in angiogenesis. Angiogenic endothelial cells require uPA and plasmin to degrade 
ECM components and migrate. However, plasmin proteolysis needs to be controlled by a physiological inhibitor 
such as PAI-1 to allow the stabilization of the surrounding ECM and the assembly of endothelial cells into 
channels. 
The plasminogen system, as well as other proteolytic systems [19] may also be implicated in the control of 
angiogenesis through the generation of proteolytic fragments of the ECM and/or other molecules that display 
angioregu-latory activities, either positive or negative. Much attention has been focused on angiostatin and 
endostatin, which are antiangiogenic molecules derived from plasminogen and collagen XVIII, respectively [77, 
78]. Recent studies suggest that angiostatin can be generated by limited proteolysis of plasminogen by plasmin, 
uPA, tPA, or MMPs [79, 80]. Other negative regulators are fragments of collagen type XV/restin [81] or 
collagen type IV, such as arresten, from the α1 chain [82], canstatin, from the α2 chain [83], and tumstatin, from 
the α3 chain [84-86]. Fragments from non-ECM molecules which may have an-gioinhibitory activity include at 
least MMP-2 (PEX), an-tithrombin [87], calreticulin (vasostatin) [88], and domain 5 of high-molecular-weight 
kininogen (kininostatin) [89]. However, although a large amount of information has accumulated on the 
antiangiogenic activity of these fragments, little is know about the proteolytic pathway leading to their release 
and the relevance of their biological activity in vivo. 
Unexpected role of PAI-1 in tumor angiogenesis 
The initially unexpected finding that PAI-1 is a strong negative prognostic marker in cancer could be explained 
by a simultaneous enhancement in uPA and PAI-1 expression resulting in a net excess of proteolytic activity. 
Alternatively, this paradoxical observation may be related to a potential direct role of PAI-1 in cancer cell 
migration and invasion. Based on its ability to block uPA proteolysis, PAI-1 would be anticipated to impair 
angiogenesis. However, pulmonary metastases from a sub-population of HT1080 cells were increased by 
exogenous administration of PAI-1 and reduced by injection of anti-PAI-1 antibody [90]. Studies in PAI-1 -
deficient mice have revealed an absolute requirement for PAI-1 in tumor angiogenesis. To investigate the role 
played by the host proteolytic system in tumor invasion and angiogenesis, murine malignant ker-atinocytes 
plated on a collagen gel were implanted onto the dorsal muscle fascia of uPA-, tPA-, uPA/tPA-, uPAR-
plasminogen-, or PAI-1-deficient mice [91, 92]. The absence of PAI-1 (but not of uPA, uPAR, or tPA) markedly 
impaired tumor invasion and vascularization. As the tumor cells produced PAI-1, the genotypic effect on tumoral 
angiogenesis was attributable to PAI-1 produced by host mesenchymal cells and/or sprouting endothelial cells. 
The importance of plasmin-mediated proteolysis in this model was further supported by the demonstration of 
delayed angiogenesis observed in plasminogen -/- mice [92]. Since then, the requirement for host PAI-1 during 
tumor angiogenesis has been confirmed in a fibrosarcoma model in PAI-1 -/-mice [93]. Laser-induced choroidal 
angiogenesis [94], an ocular model of pathological nontumoral angiogenesis similar to age-related macular 
degeneration and b-FGF-induced angiogenesis [95] were similarly impaired in PAI-1-deficient mice. 
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Furthermore, these in vivo observations are amply supported by results obtained in vitro in the mouse aortic ring 
model [96]. The essential role of PAI-1 in angiogenesis may be explained by the multifunctional nature of PAI-1 
(see above). Although the exact mechanism of PAI-1 action remains to be elucidated at least two models can be 
proposed. First, by protecting the ECM against excessive degradation, PAI-1 may serve to stabilize the matrix 
which acts as a scaffold required for endothelial cell migration and the coordinated assembly of endothelial cells 
into capillaries (fig. 2) [97]. Accordingly, the delayed angiogenesis observed in the absence of plasminogen 
emphasizes the importance of a tightly controlled plasmin-mediated proteolysis [92]. In addition, the 
sequestration of PAI-1 in the ECM is consistent with such a role. Thus, a precise balance between proteolytic 
enzymes and their inhibitors may be essential for endothelial cell migration and differentiation into functional 
vessels. In the aortic ring assay, no vessels form from PAI-1-deficient animals. Addition of exogenous 
recombinant PAI-1 at a physiological concentration restores microvessel sprouting, while at 'therapeutical' 
concentrations, angiogenesis is inhibited [96]. Similarly, PAI-1 inhibits bFGF-induced angiogenesis when added 
at high concentrations [98]. Thus PAI-1 appears to have a dual function displaying pro-an-giogenic activity at 
physiological concentrations and anti-angiogenic effects at high, pharmacological concentrations. 
A second mechanism of PAI-1 action during angiogenesis could be related to its capacity to interact with uPAR, 
integrins, and vitronectin, and thereby to control cell migration (see above and fig. 1). When PAI-1 is bound to 
vitronectin, the integrin adhesion site is cryptic and cellular adhesion is blocked. However, expression of uPA 
counteracts the PAI-1 anti-adhesive effect by destabilizing the interaction between vitronectin and PAI-1, 
restoring uPAR-vitronectin interaction, and allowing cellular integral access to the RGD adhesion site. Since 
cellular migration is considered to result from a succession of attachment and detachment events, this effect of 
PAI-1 would lead to a migratory phenotype. To address the mechanism of action of PAI-1, adenoviruses were 
used to deliver two mutant forms of PAI-1 to PAI-1 -deficient mice in the transplantation system mentioned 
above [92] and in the aortic ring assay [96]. The PAI-1 mutants either (i) bind vitronectin normally but fail to 
inhibit uPA or tPA or (ii) inhibit PAs normally but have negligible binding to vitronectin. In both in vitro and in 
vivo models, angiogenesis is restored only by the PAI-1 mutant that retains plasminogen activator inhibitory 
activity, demonstrating that the PAI-1 requirement is related only to its capacity to inhibit excessive proteolysis 
rather than to an interaction with vitronectin. Consistent with this, tumor angiogenesis and invasion were 
observed in vitronectin-deficient mice as well as in wild-type mice [92]. In a separate study using PAI-1 mutants, 
the inhibition of bFGF-induced angiogenesis in the CAM assay required both the anti-proteinase activity as well 
as the vitronectin-binding capacity of PAI-1 [98]. Together, these data suggest that depending on the situation, 
PAI-1 may control angiogenesis by regulating proteolytic and/or nonproteolytic events in endothelial cell 
migration. 
Therapeutic strategies targeting the PA system 
Numerous data collected for various types of solid cancer including at least cancer of the breast, gastrointestinal 
and urological tracts, lung, brain, ovary, and cervix demonstrate a strong clinical value for the plasminogen 
system in predicting disease recurrence and survival in cancer patients [37, 99, 100]. In breast cancer, the 
evaluation of tumor tissue levels of uPA and PAI-1 may help the selection of individualized patient therapy. A 
prospective randomized multicenter therapy trial validated the prognostic impact of uPA and PAI-1 in node-
negative breast cancer and demonstrated their usefulness as selection criteria for adjuvant chemotherapy [101]. 
Therefore, both clinical and experimental data render the plasminogen system a promising target for new anti-
tumor therapy concepts. Several approachs have been explored to interfere with the plasminogen system and to 
reduce tumor growth and metastatic potential [for reviews, see refs 37,42, 100]. In the last part of this review, we 
will briefly summarize the strategies aimed at targeting tumor angiogenesis through the plasminogen/PA system. 
However, several important issues should be stressed. First, in addition to potential influences on blood 
coagulation parameters, other side-effects of these treatments and dosing schedules can not be known without 
clinical application. Second there is no information regarding the stage and type of cancer for which these agents 
should be administered. In most mice models, these therapies were initiated at early stages of disease and 
maintained throughout the course of tumor progression. Finally, important lessons could be learned from the 
disappointing MMP inhibition experience [102]. 
Inhibition of the synthesis of plasminogen system components 
Studies using anti-sense approaches which lead to decreased uPA or uPAR protein levels have demonstrated 
anti-tumor effects [103-105]. Transfection of Hep3 carcinoma cells with anti-sense uPAR induces tumor 
dormancy [106]. 
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Inhibition of uPA activity 
The inhibitors of uPA are thought to decrease plasmin activation. Besides their anti-metastatic effects [for 
reviews, see refs 42, 100], some synthetic uPA inhibitors exhibit anti-angiogenic activities. uPA inhibitors such 
as benzamidine, amiloride, B-428, and B-623 reduce angiogenesis in a chicken embryo chorioallantoic 
membrane model [107]. An octamer peptide derived from the non-receptor-binding region of uPA reduces tumor 
angiogenesis in several murine models [108, 109]. 
Inhibition of uPA-uPAR interactions 
By preventing the binding of uPA to its receptor, uPAR antagonists may interfere both with pericellular 
proteolysis and cell adhesion and migration. Most approaches have focused on using linear or cyclic peptides 
based on the sequence of the growth factor domain of uPA [110, 111]. Despite the promise of such peptides, 
their usefulness in vivo remains to be established. Peptides are predicted to lack stability due to susceptibility to 
exoproteinase degradation in the plasma. High-affinity peptide ligands of uPAR that have been identified by 
phage display [112, 113] may circumvent some of the pharmacological problems typically associated with 
peptide therapy. Alternatively, anti-uPAR antibodies [114] or non-peptidic small-molecule antagonists of uPA 
binding have been described [100]. In this context, suramin inhibits uPA binding to U937 cells [115]. In 
addition, it interacts with other molecules involved in angiogenesis such as FGF, insulin-like growth factor, 
TGF-β, and others [116,117]. 
Inhibition of uPA-integrin interactions 
The effects of inhibiting uPAR-integrin interactions have not yet been studied extensively in vivo. However, the 
peptide M25 identified by phage display [118] has homology to the integrin αM and inhibits the binding of uPA 
to uPAR [119]. It inhibits leukocyte adhesion to fibrinogen, vitronectin, and endothelial cells. 
Delivery of viral vectors to suppress the plasminogen system 
Retroviral- or adenoviral-mediated overexpression of the ATF of uPA in experimental tumors in nude mice 
reduces primary tumor growth and metastasis by affecting angiogenesis [71]. Adenovirus-mediated delivery of 
anti-sense targeting uPAR induces the regression of pre-established glioblastoma tumors in vivo [105]. Although 
adenoviral transfer of PAI-1 reduces metastatic dissemination in mice with intraocular melanoma [120] or 
HT1080 tumors [121], the dose-dependent effect of PAI-1, pro-angiogenic at low concentration and anti-
angiogenic at higher ones [92, 96] (Fig. 2), raises questions about the use of PAI-1 or PAI-1 antagonists for 
inhibition of tumoral angiogenesis. 
Inhibition of plasmin activity 
As mentioned above, plasmin generated on the cell surface can be neutralized by aprotinin. A clinical trial 
reported enhanced 1-year survival with the perfusion of aprotinin during surgery performed on colorectal hepatic 
metastasis [122]. However, due to the risk of thrombosis, the use of aprotinin is limited to 'strategical' short 
periods of time characterized by an increased release of tumor cells, as during surgery. 
Exploitation of proteolytic activity 
To take advantage of the increased uPA and uPAR expression in malignant human tumors, cytotoxic agents that 
are activated by uPA or plasmin are being developed. These include proteins containing anthrax toxin fused to 
sequences cleaved specifically by uPA [123] or an-thracycline non-toxic pro-drugs that can be converted to an 
active parent drug by uPA [123], plasmin [124], or other serine proteinase such as prostate-specific antigen [125, 
126]. 
Conclusions and perspectives 
Increased understanding of the cellular and molecular mechanisms of angiogenesis constitute an essential basis 
for developing therapeutic strategies to manipulate angiogenesis either positively or negatively [127]. The 
studies on the PA system reviewed here provide ample evidence for the implication of this proteolytic system 
during tumoral angiogenesis. While the role of uPA and its receptor has been defined their inhibitor PAI-1 plays 
an unanticipated role and to date, little is known about the function of tPA in angiogenesis. The data 
accumulated so far raise the possibility for interfering with the plasminogen activator/plasmin system to 
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counteract angiogenesis. The adequacy of interfering with PAI-1 requires further investigations. Therefore, 
despite recent advances in angiogenesis research, many questions remain unanswered while others are emerging. 
Another process comparable to angiogenesis, called lymphangiogenesis, is responsible for the formation of new 
vessels in the lymphatic system and is believed to influence tumor invasion [128]. Although very little is known 
about the mechanisms of lymphangiogenesis, VEGF-A, VEGF-C, and bFGF are capable of stimulating uPA, 
uPAR, tPA, and PAI-1 in bovine large-vessel lymphatic endothelial cells [129, 130]. Clearly, both 
lymphangiogenesis and sprouting angiogenesis participate in tumor vasculature and have become key targets in 
the war against cancer. 
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